
    
      In this study, there will be two arms (or groups). One arm will receive Velcade, thalidomide,
      and dexamethasone (VTD), and the other arm will receive VTD with Adriamycin.

      This study has the following specific goal:

      To evaluate the efficacy and toxicity of two treatments in multiple myeloma patients,
      relapsing after at least one course of high-dose treatment and an autologous stem cell
      transplant, or after at least two lines of conventional chemotherapy.
    
  